StockPriceToday
Allogene Therapeutics Inc. (ALLO)
About Allogene Therapeutics Inc.
Allogene Therapeutics Inc. operates as a clinical-stage biotechnology company focused on developing allogeneic CAR-T cell therapies for cancer treatment using advanced cellular engineering technologies. The company's innovative approach makes ALLO stock price particularly sensitive to clinical trial results and developments in cellular immunotherapy.
The company's allogeneic CAR-T platform uses donor immune cells that are genetically engineered to target cancer cells, potentially offering advantages over autologous CAR-T therapies including reduced manufacturing time, improved consistency, and enhanced scalability. Allogene's technology could make CAR-T therapy more accessible to cancer patients.
ALLO stock price reflects investor interest in next-generation cellular immunotherapy approaches that could address limitations of current CAR-T treatments, including manufacturing complexity and treatment delays. The company's pipeline includes programs targeting various blood cancers and solid tumors.
Allogene Therapeutics' partnerships with leading academic institutions and biotechnology companies enhance its research capabilities and clinical development expertise. The company's focus on manufacturing innovation and regulatory advancement positions ALLO stock price to benefit from successful clinical outcomes and potential regulatory approvals in the evolving cellular immunotherapy market.
ALLO Stock 12 Month Chart
Latest News for ALLO
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have lost about 12.2% in that time frame, underperforming the S&P 500. But investors have to be wondering, ...
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of ...
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its ...
Other Popular Stocks
Taysha Gene Therapies Inc. (TSHA) is a clinical-stage gene therapy company developing AAV-based gene therapies for monogenic diseases of the central nervous system, focusing...
LivePerson Inc. (LPSN) is a technology company providing artificial intelligence-powered conversational commerce and customer engagement platforms for enterprises worldwide.
Hello Group Inc. (MOMO) is a social networking company providing mobile-based social discovery and entertainment platforms primarily in China.